Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices

BACKGROUND: Colony-stimulating factors (CSFs) significantly decrease the risk of febrile neutropenia (FN), a common complication of myelo suppressive chemotherapy. Pegfilgrastim (6 mg), introduced in 2002, has a sustained duration of action, with a single dose comparable in efficacy to daily injecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Vicki A., Wong, Mitchell, Hershman, Dawn, Campos, Luis T., Ding, Beiying, Malin, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2007
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437874/
https://www.ncbi.nlm.nih.gov/pubmed/17506600
http://dx.doi.org/10.18553/jmcp.2007.13.4.337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437874/
https://www.ncbi.nlm.nih.gov/pubmed/17506600
http://dx.doi.org/10.18553/jmcp.2007.13.4.337

Ejemplares similares